IQVIA (IQV) Stock Price, News & Analysis

Company Overview

IQVIA is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company leverages artificial intelligence, real-world data and extensive domain expertise to help biopharmaceutical, biotechnology and medical device companies accelerate clinical development and improve commercialization outcomes. Its offerings span the full product life cycle, from early‐stage research to post‐approval safety and market access strategies.

The firm’s core services include clinical development and operations, regulatory consulting, real‐world evidence generation, and commercial analytics. IQVIA’s clinical research capabilities encompass trial design, site management, patient recruitment and data management, while its technology platforms integrate data warehousing, advanced analytics and machine learning to deliver actionable insights. The company also provides consulting services focused on market access, pricing and health economics to support launch and reimbursement strategies.

IQVIA was formed in May 2016 through the combination of IMS Health and Quintiles, two established leaders in healthcare information and contract research, respectively. Headquartered in Durham, North Carolina, IQVIA has grown rapidly by expanding its data resources and investing in technology-driven solutions. Under the leadership of Chief Executive Officer Ari Bousbib, the company has emphasized innovation in real-world data and artificial intelligence to address evolving industry challenges.

Operating in more than 100 countries, IQVIA serves a diverse client base that includes pharmaceutical and biotechnology firms, medical device manufacturers, academic institutions, government agencies and payers. Its global footprint and integrated service model enable cross‐border collaboration and the delivery of consistent solutions across multiple therapeutic areas. By combining extensive data assets with advanced analytics capabilities, IQVIA aims to help its clients bring new therapies to market more efficiently and improve patient outcomes worldwide.

Key Stats

• Today's Range: $202.78 to $206.13
• 50-Day Range: $176.72 to $206.84
• 52-Week Range: $134.65 to $237.21
• Volume: 302,043 shs
• Average Volume: 1.83 million shs
• Market Capitalization: $34.62 billion
• P/E Ratio: 29.48
• Dividend Yield: N/A
• Price Target: $234.57
• Consensus Rating: Moderate Buy

IQVIA Stock Analysis - MarketRank™

IQVIA scored higher than 95% of companies evaluated by MarketBeat, and ranked 42nd out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IQVIA has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 18 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

IQVIA has a consensus price target of $234.57, representing about 15.2% upside from its current price of $203.54.

Amount of Analyst Coverage

IQVIA has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.55%

Earnings Growth

Earnings for IQVIA are expected to grow by 12.55% in the coming year, from $10.84 to $12.20 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IQVIA is 29.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 232.40.

Price to Earnings Ratio vs. Sector

The P/E ratio of IQVIA is 29.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 84.69.

Price to Earnings Growth Ratio

IQVIA has a PEG Ratio of 2.23. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

IQVIA has a P/B Ratio of 6.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.66% of the float of IQVIA has been sold short.

Short Interest Ratio / Days to Cover

IQVIA has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IQVIA has recently decreased by 4.06%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IQVIA does not currently pay a dividend.

Dividend Growth

IQVIA does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.69

Percentage of Shares Shorted

2.66% of the float of IQVIA has been sold short.

Short Interest Ratio / Days to Cover

IQVIA has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IQVIA has recently decreased by 4.06%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.99

News Sentiment

IQVIA has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for IQVIA this week, compared to 26 articles on an average week.

Search Interest

12 people have searched for IQV on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added IQVIA to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IQVIA insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,207,440.00 in company stock.

Percentage Held by Insiders

Only 1.60% of the stock of IQVIA is held by insiders.

Percentage Held by Institutions

89.62% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IQV Stock Analysis - Frequently Asked Questions

How have IQV shares performed this year?

IQVIA's stock was trading at $196.51 at the beginning of 2025. Since then, IQV stock has increased by 3.6% and is now trading at $203.54.

How were IQVIA's earnings last quarter?

IQVIA Holdings Inc. (NYSE:IQV) issued its quarterly earnings results on Tuesday, July, 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. The firm's quarterly revenue was up 5.3% on a year-over-year basis.
Read the conference call transcript.

Does IQVIA have any subsidiaries?

IQVIA subsidiaries include these companies: Q2 Solutions, Linguamatics, Advanced Health Media LLC, DrugDev, Aileron Solutions, Novella Clinical LLC, 159 Solutions LLC, and more.

Who are IQVIA's major shareholders?

IQVIA's top institutional shareholders include Pacer Advisors Inc. (0.43%), Vontobel Holding Ltd. (0.32%), Assenagon Asset Management S.A. (0.14%) and Howard Capital Management Group LLC (0.08%). Insiders that own company stock include Ari Bousbib, Eric Sherbet, Constantinos Panagos, Kevin C Knightly, Keriann Cherofsky and John G Danhakl.
View institutional ownership trends.

How do I buy shares of IQVIA?

Shares of IQV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IQVIA own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IQVIA investors own include NVIDIA (NVDA), Chevron (CVX), Meta Platforms (META), Bristol Myers Squibb (BMY), Advanced Micro Devices (AMD), Broadcom (AVGO) and McKesson (MCK).

Company Calendar

• Last Earnings: 7/22/2025
• Today: 10/16/2025
• Next Earnings (Estimated): 10/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Business Services
• Current Symbol: NYSE:IQV
• CIK: 1478242
• Web: www.iqvia.com
• Phone: (919) 998-2000
• Fax: N/A
• Employees: 88,000
• Year Founded: 2016

Price Target and Rating

• Average Price Target for IQVIA: $234.57
• High Price Target: $270.00
• Low Price Target: $177.00
• Potential Upside/Downside: +13.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.91
• Trailing P/E Ratio: 29.81
• Forward P/E Ratio: 19.00
• P/E Growth: 2.23
• Net Income: $1.37 billion
• Net Margins: 7.88%
• Pretax Margin: 9.80%
• Return on Equity: 30.05%
• Return on Assets: 6.77%

Debt

• Debt-to-Equity Ratio: 2.45
• Current Ratio: 0.84
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $15.41 billion
• Price / Sales: 2.27
• Cash Flow: $16.84 per share
• Price / Cash Flow: 12.23
• Book Value: $33.43 per share
• Price / Book: 6.16

Miscellaneous

• Outstanding Shares: 170,000,000
• Free Float: 167,280,000
• Market Cap: $35.01 billion
• Optionable: Optionable
• Beta: 1.32